Attending ISDS or ASBMR? Check out our presentations on TYRA-300’s preclinical results in achondroplasia and hypochondroplasia. We are excited to showcase our science at ISDS and ASBMR, which represent two of the premier scientific meetings focused on advancing research for bone disorders. More information below: https://isdsmadrid2024.com https://lnkd.in/detF7ZZ #ISDS2024 #ASBMR2024
Tyra Biosciences
Biotechnology
Carlsbad, California 3,143 followers
TYRA is focused on developing next-generation precision medicines that target large opportunities in FGFR biology.
About us
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables the rapid and precise refinement of structural drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.
- Website
-
http://tyra.bio
External link for Tyra Biosciences
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Carlsbad, California
- Type
- Public Company
- Specialties
- Biotechnology, oncology, Achondroplasia, FGFR biology, and Structural drug design
Locations
-
Primary
Carlsbad, California, US
Employees at Tyra Biosciences
Updates
-
Next week, Todd Harris, CEO of TYRA, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference. Learn more here: https://bit.ly/3AXHLGx #CantorGlobalHealthcare #Biotech
-
Tyra Biosciences announced today the appointment of Doug Warner, M.D., as Chief Medical Officer. Dr. Warner brings over twenty years of proven clinical development leadership to TYRA, having successfully led global development and secured approvals for medicines across oncology and skeletal disease. Please join us in welcoming Doug! Read more here: https://bit.ly/4ghf1Jd #biotech #leadership
-
We are pleased to present the science behind TYRA-300 in the First Time Disclosures section at #ACSFall2024. Dr. Robert L. Hudkins, our Chief Technology Officer, will be speaking tomorrow, August 21st, 2024 at 6:15 pm EDT. More information on the meeting can be found here: https://bit.ly/4dsgIll #ACSFall2024
-
Today, Tyra Biosciences reported financial results for the quarter ended June 30, 2024, and highlighted recent corporate progress. Learn more here: https://bit.ly/4fEon1s
-
#Pharmachon 2024 is a wrap! We were pleased to highlight our newest research on TYRA-300 in HCH, while collaborating with industry colleagues, patient advocates and scientific leaders in the field of skeletal dysplasias. Looking forward to next year! More details here: https://bit.ly/45PoO4k
-
Today, we announced preclinical proof-of-concept results with TYRA-300, an investigational oral FGFR3 selective inhibitor, in hypochondroplasia (HCH). Learn more here: https://bit.ly/3RSPU4C
-
We are pleased to introduce our Senior Vice President of Human Resources, Liz Pagano! Liz is a results-oriented leader who brings over 25 years of experience to TYRA, with a wealth of expertise in team building, culture creation and growth strategies. Join us in welcoming Liz! #biotech #leadership
-
At #ICCBH2024 today, we showcased preclinical data in achondroplasia on our oral, FGFR3-selective inhibitor, TYRA-300, during an oral presentation. This meeting brings together scientists and clinicians from across the globe to gain a better understanding of the growing skeleton in health and disease. We were thrilled to participate, and we thank the conference organizers for highlighting our scientific research in achondroplasia. More details here: https://bit.ly/4cB3WQo #ICCBH2024 #achondroplasia #ACH
-
Tyra Biosciences announced today that company management will present at upcoming investor conferences. More info here: https://bit.ly/4bT32P5